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Solid organ transplantation has greatly improved survival in children with end-stage disease, becoming one of
the main treatment options in this population. Nonetheless, there are significant challenges associated with
validating and optimizing the effects of these interventions in clinical trials. Therefore, we reviewed the main
issues related to conducting clinical transplantation research in children. We divided these challenges into three
different categories: (i) challenges related to surgical techniques and anesthetic procedures, (ii) challenges
related to post-transplant care and (iii) challenges specific to a particular population group and disease type.
Some of the observed burdens for clinical research in this field are related to the limitations of conducting
studies with a placebo or sham procedure, determining the standard of care for a control group, low
prevalence of cases, ethical concerns related to use of a placebo control group and lack of generalizability from
animal studies and clinical trials conducted in adult populations. To overcome some of these barriers, it is
necessary to utilize alternative clinical trial designs, such as observational studies or non-inferiority trials, and to
develop multicenter collaborations to increase the recruitment rate. In conclusion, the lack of robust data
related to pediatric transplantation remains problematic, and further clinical trials are needed to develop more
efficacious and safer treatments.
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& INTRODUCTION
Solid organ transplantation has become the mainstay of
treatment for children with end-stage heart, kidney, lung
and liver diseases, improving survival and life expectancy
in up to 80% of patients. The history of solid organ trans-
plantation dates back to 1952, when the first pediatric
kidney transplant was performed (1), followed by the first
liver transplant in 1963 (2) and the first heart transplant in
1967 (3). Since these early successes, the development and
constant improvement of surgical techniques, anesthetic
procedures (4-6) and post-transplantation care, especially
immunosuppressive therapy, have greatly increased the
rate of graft success and have improved recipient outcomes
(7-10).
Despite the progress made in the field of pediatric
transplantation in recent years, the clinical development of
this therapeutic approach remains a fundamental challenge,
mainly due to inherent issues related to conducting clinical
transplantation research in children. These issues can be
categorized as those associated with the study of surgical
techniques and anesthetic procedures, those related to
post-transplant care, including the study of immunosup-
pressive therapy, and challenges specific to the disease type
and population group.
& CHALLENGES FOR SURGICAL AND ANESTHETIC
TECHNIQUE RESEARCH
Research exploring surgical techniques for pediatric solid
organ transplantation poses several burdens on research-
ers. For example, the use of placebo or sham procedures is
both ethically and logistically unviable, making it impos-
sible to include a control group in clinical trials. It is also
difficult to establish a clear definition for standard of
care due to the constant evolution of surgical techniques,
innovation in operative instruments, changes in the criteria
for donor and recipient selection, improvements in perio-
perative management and the continuing perfection of
anesthetic procedures. Consequently, the comparability
and translation of the results is limited. Due to the low
number of cases per year, most clinical trials resort to the
use of multiple research centers to meet their participant
accrual and enrollment requirements, which can introduce
bias to the study related to the variability in surgical
procedures among centers and the grade of expertise
among surgeons.
Conducting observational studies is valuable; however,
similar confounders, mainly those associated with varia-
bility in donor and recipient selection criteria and in surgical
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technique and expertise among centers, can obscure and
limit the results.
& CHALLENGES FOR POST-TRANSPLANT CARE
RESEARCH
Post-surgical management is an essential part of trans-
plant care, and a high percentage of the success of solid
organ transplants can be attributed to the improvement in
peri- and post-operative care of these patients, including
immunosuppression therapy. Research studies evaluating
the efficacy and safety of immunosuppressive therapies for
solid organ post-transplant care are difficult to design and
conduct (11). Most of the challenges associated with this
type of trial are related to ethical concerns of using placebo
in the control group. Only a few randomized clinical trials
have been conducted, and most of these compare a new
intervention combined with standard treatment to standard
treatment alone (12,13) or opt for a non-inferiority design,
comparing the new intervention to standard treatment (14).
The main limitations of these two types of designs are the
large sample size required to achieve good power and poor
generalizability of the results because of the strict selection
criteria and lack of a true placebo-control group. Due to
these limitations, most researchers opt for observational
studies; however, this type of design has inherent restric-
tions associated with the effects of potential confounders on
the results.
The lack of consensus and standardization of post-
transplant care in pediatric patients is also a major limitation
for the design of clinical trials and for drawing conclusions
that can be used in the clinical setting. A recent systematic
review conducted by Gijsen et al. (15) reported a wide range
of definitions for inclusion criteria and high variability
among measurements in the 18 trials included, demonstrat-
ing that these disparities can be a significant barrier to the
improvement of clinical research in pediatric transplanta-
tion. Similar findings were reported by Rothbaum and
colleagues (16), emphasizing the lack of strong evidence in
the field.
Results from in vitro studies and animal models cannot
always be translated to in vivo outcomes, mainly because
they are unable to accurately predict the effects of new
therapeutic molecules in the dynamic donor-recipient
relationship or reflect their influence on disease type and
severity. Extrapolation of the results from research explor-
ing similar diseases is not always possible because of
the specific effects of this therapeutic procedure on the
pathophysiological mechanisms of each condition.
& CHALLENGES INHERENT TO DISEASE TYPE AND
POPULATION GROUP
Most clinical trials and observational studies in this field
include only adult participants; these studies are commonly
used as guidelines for decision-making related to trans-
plantation in children. However, the generalizability of
results obtained with adults to pediatric populations is
limited and should be assessed carefully. The effects and
success of transplantation in children can significantly differ
from that in adults, mainly because of specific aspects such
as growth and development, differences in the classification
of severity in end-stage diseases and criteria for recipient
selection, which can highly influence graft viability and
success.
The small number of solid organ transplantations
performed in pediatric patients per year remains an
important challenge for research in this field, and it is even
more evident when the analysis is focused on organs such
as the heart and lung. Sweet et al. (17) reported that 125
pediatric lung transplantations were performed annually
worldwide, with an average of 2-3 transplants per center per
year.
Randomization of children in the context of a clinical trial
poses major ethical concerns, especially when new interven-
tions are being tested. Obtaining informed consent either
from the subjects themselves or from parents and legal
guardians is a major barrier for randomized clinical trials
(RCTs) in pediatric populations (18,19). The Zelen designwas
implemented as an alternative to conventional RCTs, allow-
ing researchers to seek consent from the patient or parents
after randomization is completed. Therefore, participants are
asked to consent to receiving a specific treatment and not to
being randomized in the trial, which increases the accrual
rate given that subjects are aware of their allocation at the
moment of consent. The first example of this randomization
approach was the extracorporeal membrane oxygenation
trial, which tested the effects of extracorporeal membrane
oxygenation in neonates with severe pulmonary hyperten-
sion (20). To date, no adaptations of the Zelen design have
been reported in the transplant literature.
& STRATEGIES FOR OVERCOMING CHALLENGES IN
PEDIATRIC ORGAN TRANSPLANT RESEARCH
Given all of these challenges, researchers in pediatric
transplantation should be aware of potential alternatives
that can aid in overcoming the barriers to clinical research in
this field. Such alternatives should be implemented when-
ever possible.
Observational studies can be a solution for overcoming
ethical concerns related to RCTs. These studies should be
carefully designed, and researchers must be aware of and
actively think about potential confounders that may obscure
the results. These potential cofounders should be accounted
for both at the moment of design and during data analysis.
The development of pragmatic trials can also be an
alternative to research in pediatric transplantation, as they
allow the effects of an intervention to be studied in real-life
routine practice conditions and can be extended to more
complex and robust explanatory trials.
As previously mentioned, some of the limitations of
RCTs, both in surgical and clinical scenarios of pediatric
transplantation, are associated with the inability to translate
the results obtained from adult studies and from pediatric
studies examining similar diseases and procedures. For
researchers to overcome these barriers, it is necessary to
have a clearer understanding of the mechanisms that
determine success or failure of transplantation in children
and how they differ from those in adults and in other
diseases.
Another major challenge is related to the small number of
pediatric transplantation cases per year. Several initiatives
have been created to aid this purpose, with the aim of
consolidating a strong network of transplant centers with
unified criteria for patient selection, standard surgical
procedures and post-operative care. These initiatives also
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aim to create a large registry of pediatric solid-organ
transplant recipients for future observational research in
the field. For example, the International Pediatric Lung
Collaborative (IPLTC) (17) and the Pediatric Heart
Transplant Study Group (PHTS) (21) were created for this
purpose and have been successful in terms of consolidating
a strong database for observational studies in this area. The
National Institute of Allergies and Infectious Diseases
designed a helpful strategy that aims to increase the number
of trials conducted in pediatric transplant recipients,
referred to as Clinical Trials in Organ Transplantation in
Children (CTOT-C) (22). The goal of this initiative is to
improve the understanding of the immune factors that play
a role in transplant success. To date, approximately 10
clinical trials have been approved and are actively recruit-
ing. More than 70 research centers in 50 different academic
institutions are involved in this initiative.
In conclusion, there are fundamental challenges related to
the design and execution of clinical trials and observational
studies for pediatric solid-organ transplantation. Efforts
should be made to develop alternatives that can help
researchers overcome some of these challenges so that
evidence in this field can be strengthened and clinical practice
can be based on robust results from well-designed studies.
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